BRIEF published on 04/16/2024 at 13:05, 2 years 4 months ago CureVac et MD Anderson collaborent sur des vaccins innovants contre le cancer Technologie ARNm CureVac MD Anderson Vaccins Contre Le Cancer Collaboration Biopharmaceutique
PRESS RELEASE published on 04/16/2024 at 13:00, 2 years 4 months ago CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines CureVac and MD Anderson announce strategic collaboration to develop mRNA-based cancer vaccines, leveraging respective expertise to address unmet medical needs in hematological and solid tumors Clinical Research Collaboration CureVac MD Anderson MRNA-based Cancer Vaccines
BRIEF published on 04/04/2024 at 13:05, 2 years 4 months ago CureVac Reports Positive Phase 2 Results for Influenza Vaccine in Collaboration with GSK GSK MRNA Technology CureVac Influenza Vaccine Phase 2 Trial
BRIEF published on 04/04/2024 at 13:05, 2 years 4 months ago CureVac annonce des résultats positifs de phase 2 pour son vaccin contre la grippe en collaboration avec GSK GSK Technologie ARNm CureVac Vaccin Contre La Grippe Essai De Phase 2
PRESS RELEASE published on 04/04/2024 at 13:00, 2 years 4 months ago CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK CureVac announces positive Phase 2 interim results for seasonal influenza vaccine in collaboration with GSK, showing strong antibody titers and safety profile GSK CureVac Phase 2 Seasonal Influenza Vaccine MRNA
PRESS RELEASE published on 11/01/2023 at 13:00, 2 years 9 months ago CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
PRESS RELEASE published on 09/28/2023 at 13:00, 2 years 11 months ago CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
PRESS RELEASE published on 09/12/2023 at 13:15, 2 years 11 months ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 09/12/2023 at 13:00, 2 years 11 months ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 08/17/2023 at 13:00, 3 years ago CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Published on 08/28/2026 at 13:00, 55 minutes ago Abasca Files NI 43-101 Technical Report, Commences Summer Exploration Program at Loki and Elects to File Semi-annual Interim Financial Statements and Related MD&A
Published on 08/28/2026 at 08:05, 5 hours 50 minutes ago Caledonia Mining Corporation Plc: Maiden Mineral Resource Estimate at Motapa 379,000 oz Measured and Indicated; 131,000 oz Inferred
Published on 08/28/2026 at 08:05, 5 hours 50 minutes ago Tocvan Announces New Surface Mineralization in Several Zones at Gran Pilar Gold-Silver Project
Published on 08/28/2026 at 08:00, 5 hours 55 minutes ago Caledonia Mining Corporation Plc: Blanket Mine Underground Measured and Indicated Mineral Resources Estimate Increases by 22% to 2.18 Million Ounces and Declaration of a Surface Mineral Resource Estimate
Published on 08/28/2026 at 04:30, 9 hours 25 minutes ago Snipp Interactive Reports Q2 2026 Financial Results; Returns to Positive EBITDA on Highest Quarterly Revenue in Five Quarters
Published on 08/28/2026 at 13:44, 11 minutes ago Original-Research: Aroundtown SA (von First Berlin Equity Research GmbH): Kaufen
Published on 08/28/2026 at 12:43, 1 hour 12 minutes ago Annual General Meeting of MPC Capital AG approves change of name to MPC Oceanic Group AG
Published on 08/26/2026 at 18:02, 1 day 19 hours ago Altareit: Altarea press release regarding the Primonial matter
Published on 08/26/2026 at 18:02, 1 day 19 hours ago Altareit : Communiqué de presse d’Altarea relatif au dossier Primonial
Published on 08/26/2026 at 18:00, 1 day 19 hours ago Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
